556
Views
33
CrossRef citations to date
0
Altmetric
Original Research

Risk factors for weight gain during methadone maintenance treatment

, PhD, , MD, , MA & , MD

References

  • Rajs J, Petersson A, Thiblin I, Olsson-Mortlock C, Fredriksson A, Eksborg S. Nutritional status of deceased illicit drug dependent in Stockholn, Sweden—a longitudinal medicolegal study. J Forensic Sci. 2004;49:1–10.
  • Nolan LJ, Scagnelli LM. Preference for sweet foods and higher body mass index in patients being treated in long-term methadone maintenance. Subst Use Misuse. 2007;42:1555–1566.
  • Okruhlica L, Slezáková S. Weight gain among the patients in methadone maintenance program as come-back to population norm. Cas Lek Cesk. 2008;147:426–430.
  • Fenn JM, Laurent JS, Sigmon SC. Increases in body mass index following initiation of methadone treatment. J Subst Abuse Treat. 2015;51:59–63.
  • Mysels DJ, Vosburg SK, Benga I, Levin FR, Sullivan MA. Course of weight change during naltrexone versus methadone maintenance for opioid-dependent patients. J Opioid Manag. 2011;7:47–53.
  • Okruhlica Ĺ, Slezáková S. Weight changes of patients in methadone maintenance treatment during four years period [in Slovak]. Cas Lek Cesk. 2012;151:389–391.
  • Montazerifar F, Karajibani M, Lashkaripour K. Effect of methadone maintenance therapy on anthropometric indices in opioid dependent patients. Int J High Risk Behav Addict. 2012;1:100–103.
  • Reimer J, Verthein U, Karow A, Schäfer I, Naber D, Haasen C. Physical and mental health in severe opioid-dependent patients within a randomized controlled maintenance treatment trial. Addiction. 2011;106:1647–1655.
  • World Health Organization. Obesity and overweight. http://www.who.int/mediacentre/factsheets/fs311/en/#. Accessed June 30, 2016.
  • Falahi E, Khalkhali Rad AH, Roosta S. What is the best biomarker for metabolic syndrome diagnosis? Diabetes Metab Syndr. 2015;9:366–372.
  • Howard AA, Hoover DR, Anastos K, et al. The effects of opiate use and hepatitis C virus infection on risk of diabetes mellitus in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr. 2010;54:152–159.
  • Mack M, Gopal A. Epidemiology, traditional and novel risk factors in coronary artery disease. Cardiol Clin. 2014;32:323–332.
  • Zador D, Lyons Wall PM, Webster I. High sugar intake in a group of women on methadone maintenance in southwestern Sydney, Australia. Addiction. 1996;91:1053–1061.
  • Bogucka-Bonikowska A, Baran-Furga H, Chmielewska K, et al. Taste function in methadonemaintained opioid-dependent men. Drug Alcohol Depend. 2002;68:113–117.
  • Howard AA, Floris-Moore M, Lo Y, Arnsten JH, Fleischer N, Klein RS. Abnormal glucose metabolism among older men with or at risk of HIV infection. HIV Med. 2006;7:389–396.
  • Fareed A, Casarella J, Amar R, Vayalapalli S, Drexler K. Benefits of retention in methadone maintenance and chronic medical conditions as risk factors for premature death among older heroin addicts. J Psychiatr Pract. 2009;15:227–234.
  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed., text revision. Washington, DC: American Psychiatric Press; 2000.
  • Adelson M, Peles E, Bodner G, Kreek MJ. Correlation between high methadone doses and methadone serum levels in methadone maintenance treatment (MMT) patients. J Addict Dis. 2007;26:15–26.
  • Hawk RL. Analytical methodology. NIDA Res Monogr. 1986;73:30–42.
  • McLellan AT, Luborsky L, O'Brien CP, Barr HL, Evans F. The addiction severity index in three different populations. NIDA Res Monogr. 1984;55:217–223.
  • Peryam DR, Pilgrim FJ. Hedonic scale method of measuring food preferences. Food Technol. 1957;11:9–14.
  • Moynihan PJ, Mulvaney CE, Adamson AJ, et al. The nutrition knowledge of older adults living in sheltered housing accommodation. J Hum Nutr Diet. 2007;20:446–458.
  • Mouly S, Bloch V, Peoc'h K, et al. Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity. Br J Clin Pharmacol. 2015;79:967–977.
  • Levran O, Peles E, Randesi M, et al. Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction. Pharmacogenomics. 2013;14:755–768.
  • Peles E, Schreiber S, Hamburger RB, Adelson M. No change of sleep after 6 and 12 months of methadone maintenance treatment. J Addict Med. 2011;5:141–147.
  • Berger G, Berger R, Oksenberg A. Progression of snoring and obstructive sleep apnoea: the role of increasing weight and time. Eur Respir J. 2009;33:338–345.
  • Peles E, Schreiber S, Adelson M. 15-Year survival and retention of patients in a general hospital-affiliated methadone maintenance treatment (MMT) center in Israel. Drug Alcohol Depend. 2010;107:141–148.
  • Sansone RA, Sansone LA. Marijuana and body weight. Innov Clin Neurosci. 2014;11:50–54.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.